复方苦参注射液联合DCF化疗方案对胃癌术后患者并发症及Th17/Treg平衡的影响  

Effects of Compound Kushen Injection Combined with DCF Chemotherapy Regimen on Postoperative Complications and Th17/Treg Balance in Patients with Gastric Cancer

作　　者：张浩[1] 刘岗[1] 蒋海锋[1] 张熹玮[1] ZHANG Hao;LIU Gang;JIANG Haifeng;ZHANG Xiwei(Dept.of General Surgery,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200021,China)

机构地区：[1]上海中医药大学附属曙光医院普外科,上海200021

出　　处：《中国医院用药评价与分析》2024年第7期793-796,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：上海市中医药三年行动计划(2021-2023)项目[No.ZY(2021-2023)-0201-02]。

摘　　要：目的:探讨复方苦参注射液联合DCF化疗方案对胃癌术后患者并发症及Th17/Treg平衡的影响。方法:选取2022年10月至2023年8月于该院进行手术治疗的胃癌患者96例,根据治疗方案的不同分为复方苦参注射液组和对照组,每组48例。两组患者均接受根治性手术治疗,对照组患者采用DCF化疗方案(多西他赛+顺铂+5-氟尿嘧啶)治疗,复方苦参注射液组患者在对照组的基础上加用复方苦参注射液治疗。比较两组患者并发症发生率,Th17、Treg和Th17/Treg指标变化情况。结果:复方苦参注射液组患者的并发症发生率为10.42%(5/48),低于对照组的35.42%(17/48),差异有统计学意义(P<0.05)。治疗后,两组患者Th17、Th17/Treg指标高于治疗前,且复方苦参注射液组患者明显高于对照组,差异均有统计学意义(P<0.05);治疗后,两组患者Treg指标低于治疗前,且复方苦参注射液组患者明显低于对照组,差异均有统计学意义(P<0.05)。结论:复方苦参注射液能够调节胃癌术后患者体内T细胞亚群失衡,改善机体免疫功能,减轻术后并发症发生率,更有利于患者预后。OBJECTIVE:To probe into the effects of compound Kushen injection combined with DCF chemotherapy regimen on postoperative complications and Th17/Treg balance in patients with gastric cancer.METHODS:Totally 96 patients with gastric cancer who underwent surgical treatment in the hospital from Oct.2022 to Aug.2023 were extracted to be divided into the compound Kushen injection group and control group according to different treatment regimens,with 48 cases in each group.Both groups received radical surgery.The control group was treated with DCF chemotherapy regimen(docetaxel+cisplatin+5-fluorouracil),while the compound Kushen injection group received compound Kushen injection on the basis of the control group.The incidence of postoperative complications and changes in Th17,Treg,and Th17/Treg indicators were compared between two groups.RESULTS:After treatment,the incidence of complications in compound Kushen injection group was 10.42%(5/48),lower than 35.42%(17/48)in control group,the difference was statistically significant(P<0.05).After treatment,Th17 and Th17/Treg indicators in both groups were higher than those before treatment,and the compound Kushen injection group was significantly higher than the control group,the differences were statistically significant(P<0.05).After treatment,Treg indicators in both groups were lower than those before treatment,and the compound Kushen injection group was significantly lower than the control group,with statistically significant difference(P<0.05).CONCLUSIONS:Compound Kushen injection can regulate the imbalance of T cell subsets in patients with gastric cancer after surgery,improve immune function,reduce the incidence of postoperative complications,and is more conducive to the prognosis of patients.

关 键 词：复方苦参注射液 DCF化疗 胃癌 并发症 Th17/Treg平衡 

分 类 号：R979.1[医药卫生—药品]